CABOZANTINIB
BREAKPOINT
Phase 2 small_molecule active
Quick answer
CABOZANTINIB for Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors. is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active